PLANTATION, Fla., Nov. 20, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI) [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=1931949497&u=https%3A%2F%2Fwww.gbibio.com%2F&a=GBI+Biomanufacturing+(GBI)], one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP) services [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3432038397&u=https%3A%2F%2Fwww.gbibio.com%2Faseptic-fill-finish%2F&a=services], to include automated sterile fill and finish capabilities. GBI has the ability to support clients from clinical trials to commercial [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=30581841&u=https%3A%2F%2Fwww.gbibio.com%2Fgbi-secures-commercial-manufacturing-contract-solidifying-leadership-in-radiopharmaceutical-manufacturing%2F&a=commercial] launch, for both Drug Substance (DS) and DP [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3631185719&u=https%3A%2F%2Fwww.gbibio.com%2Fcgmp-clinical-commercial-manufacturing%2F&a=Drug+Substance+(DS)+and+DP], all at its one location in Florida, USA. This addition demonstrates GBI's commitment to delivering advanced and flexible Single-Source Solutions(TM) for the rapidly evolving pharmaceutical and biotech industries.
https://mma.prnewswire.com/media/2523494/GBI_Biomanufacturing.jpg [https://mma.prnewswire.com/media/2523494/GBI_Biomanufacturing.jpg]
The ability to provide an in-house, dual approach of automated and manual sterile fill finish [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=2781734562&u=https%3A%2F%2Fwww.gbibio.com%2Ffuture-trends-in-sterile-fill-finish-technology-whats-on-the-horizon%2F&a=sterile+fill+finish], enables GBI [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=189597288&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgbi-bio%2F&a=GBI] to meet the diverse needs of its clients with precision and efficiency. For smaller, early-stage clinical batches or products requiring special handling, manual aseptic vial filling [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3455773294&u=https%3A%2F%2Fwww.gbibio.com%2Fhow-sterile-fill-finish-aseptic-techniques-ensure-drug-integrity-and-patient-safety%2F&a=aseptic+vial+filling] offers flexibility and control. Automated aseptic liquid filling [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=2627028338&u=https%3A%2F%2Fwww.gbibio.com%2Faseptic-fill-finish-manufacturing%2F&a=aseptic+liquid+filling] employing ready-to-use components supports higher-throughput production with minimal human intervention, reducing the risk of contamination and increasing batch consistency, making it ideal for both clinical and commercial-scale projects.
"Adding automated aseptic fill-finish [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3230981852&u=https%3A%2F%2Fwww.gbibio.com%2Fwp-content%2Fuploads%2F2022%2F11%2Fgoodwin_ast_pr_final__nci_.pdf&a=aseptic+fill-finish] capabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies," said Karl Pinto [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=1635832947&u=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fkarl-pinto-7397022%3Flipi%3Durn%253Ali%253Apage%253Ad_flagship3_profile_view_base_contact_details%253BYn%252FLKO%252BwT2WrER5Y0BpC5g%253D%253D&a=Karl+Pinto], & CEO at GBI. "Our facility [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3725177070&u=https%3A%2F%2Fwww.gbibio.com%2Ffacilities-and-locations%2F&a=facility] is equipped with state-of-the-art technology and a team of experts, capable of delivering high-quality, regulatory compliant drug products."
GBI's new three format automated filler has capabilities to support filling in vials, syringes and cartridges, across various drug classes such as biologics, vaccines, bioconjugates [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=507676595&u=https%3A%2F%2Fwww.gbibio.com%2Fbioconjugation%2F&a=bioconjugates] and complex large molecules [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3754583982&u=https%3A%2F%2Fwww.gbibio.com%2Fapplications%2F&a=complex+large+molecules].
The addition of these capabilities aligns with GBI's broader mission to provide its clients with end-to-end development and cGMP manufacturing [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3191527292&u=https%3A%2F%2Fwww.gbibio.com%2Fscaling-strategies-in-drug-product-process-development-from-laboratory-to-commercial-production%2F&a=end-to-end+development+and+cGMP+manufacturing] services as a Single-Source Solution(TM) CDMO. The company's enhanced fill-finish [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3624349679&u=https%3A%2F%2Fwww.gbibio.com%2Faseptic-fill-finish%2F&a=fill-finish] capacity will simplify its clients' manufacturing supply chains and help in achieving faster timelines [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3331775027&u=https%3A%2F%2Fwww.gbibio.com%2Frevolutionizing-ind-filings-with-rapid-analytics-streamlined-platform-strategies-for-faster-and-safer-biopharmaceutical-development%2F&a=faster+timelines], improved scalability, regulatory compliance and the convenience of having both DS and DP material manufactured at one site [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=2296617075&u=https%3A%2F%2Fwww.gbibio.com%2Ffacilities-and-locations%2F&a=one+site]!
About GBI
GBI is a leading CDMO focused on providing comprehensive, high-quality services to the global pharmaceutical and biotech sectors. With expertise in process development [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=2515086611&u=https%3A%2F%2Fwww.gbibio.com%2Fdsp-purification-development%2F&a=process+development], analytical services [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=2571839514&u=https%3A%2F%2Fwww.gbibio.com%2Fanalytical-method-development-assay-verification-and-characterization%2F&a=analytical+services], DS manufacturing and sterile fill finish [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=2361173050&u=https%3A%2F%2Fwww.gbibio.com%2Faseptic-fill-finish%2F&a=sterile+fill+finish] for biologics, GBI supports the development and commercialization [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3892597369&u=https%3A%2F%2Fwww.gbibio.com%2Fcgmp-clinical-commercial-manufacturing%2F&a=commercialization] of life-saving therapies worldwide.
For more information on GBI, a drug substance and sterile fill finish CDMO visit: https://www.gbibio.com/aseptic-fill-finish/ [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=1964619240&u=https%3A%2F%2Fwww.gbibio.com%2Faseptic-fill-finish%2F&a=https%3A%2F%2Fwww.gbibio.com%2Faseptic-fill-finish%2F] or contact via https://www.gbibio.com/contact/ [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=539833890&u=https%3A%2F%2Fwww.gbibio.com%2Fcontact%2F&a=https%3A%2F%2Fwww.gbibio.com%2Fcontact%2F].
Media Contact: info@GbiBio.com [mailto:info@GbiBio.com]
Logo - https://mma.prnewswire.com/media/2523494/GBI_Biomanufacturing.jpg [https://c212.net/c/link/?t=0&l=en&o=4307151-1&h=3039798427&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2523494%2FGBI_Biomanufacturing.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2523494%2FGBI_Biomanufacturing.jpg]
View original content:https://www.prnewswire.co.uk/news-releases/gbi-biomanufacturing-expands-capabilities-with-automated-aseptic-fill-finish-for-drug-products-302310878.html [https://www.prnewswire.co.uk/news-releases/gbi-biomanufacturing-expands-capabilities-with-automated-aseptic-fill-finish-for-drug-products-302310878.html]
Photo: https://mma.prnewswire.com/media/2523494/GBI_Biomanufacturing.jpg GBI Biomanufacturing
